Results 111 to 120 of about 295,503 (301)

Baseline Regional Cholinergic Denervation Predicts Cognitive Trajectories in Moderate Parkinson Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cognitive decline is a disabling and variable feature of Parkinson disease (PD). While cholinergic system degeneration is linked to cognitive impairments in PD, most prior research reported cross‐sectional associations. We aimed to fill this gap by investigating whether baseline regional cerebral vesicular acetylcholine transporter ...
Taylor Brown, Giulia Carli, Prabesh Kanel, Stiven Roytman, Jaimie Barr, Nicolaas I. Bohnen, Roger L. Albin   +6 more
wiley   +1 more source

An integrated transcriptomics and proteomics analysis reveals functional endocytic dysregulation caused by mutations in LRRK2

Neurobiology of Disease, 2019
Background: Mutations in LRRK2 are the most common cause of autosomal dominant Parkinson's disease, and the relevance of LRRK2 to the sporadic form of the disease is becoming ever more apparent.
Natalie Connor-Robson, Heather Booth, Jeffrey G. Martin, Benbo Gao, Kejie Li, Natalie Doig, Jane Vowles, Cathy Browne, Laura Klinger, Peter Juhasz, Christine Klein, Sally A. Cowley, Paul Bolam, Warren Hirst, Richard Wade-Martins   +14 more
doaj   +1 more source

Longitudinal falls data in Parkinson’s disease: feasibility of fall diaries and effect of attrition [PDF]

, 2017
Background: Identifying causes of falls for people with Parkinson’s disease has met with limited success. Prospective falls measurement using the “gold standard” approach is challenging.
Hunter, Heather, Lord, Sue, Morris, Rosie, Rochester, Lynn   +3 more
core   +4 more sources

Clinical Validation of Plasma p‐217tau in Neurological Diseases

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi, Takumi Nakamura, Ryoma Takahashi, Tetsuya Ueda, Seiji Kinoshita, Chikage Uchida, Takashi Sugawara, Kentaro Hashimoto, Kunihiko Ishizawa, Masakuni Amari, Hiroo Kasahara, Yoshio Ikeda, Masamitsu Takatama, Mikio Shoji   +13 more
wiley   +1 more source

Palliative care for Parkinson’s disease: suggestions from a council of patient and carepartners

npj Parkinson's Disease, 2017
In 2015, the Parkinson’s Disease Foundation sponsored the first international meeting on Palliative Care and Parkinson’s disease and the Patient Centered Outcomes Research Institute funded the first comparative effectiveness trial of palliative care for ...
Kirk Hall, Malenna Sumrall, Gil Thelen, Benzi M. Kluger, on behalf of the 2015 Parkinson’s Disease Foundation sponsored “Palliative Care and Parkinson’s Disease” Patient Advisory Council   +4 more
doaj   +1 more source

CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Imaging and postmortem studies indicate that abnormalities in monoaminergic neurotransmission contribute to cognitive impairment in Parkinson's disease (PD). However, it remains uncertain if cerebrospinal fluid (CSF) monoamine metabolites can serve as biomarkers of cognitive decline in early PD.
Jing‐Yu Shao, Rong Li, Yu‐Xiang Jiao, Kai Ma, Hong‐Qi Yang, Zheng‐Yu Sun, Jie‐Wen Zhang, Shuai Chen   +7 more
wiley   +1 more source

Primary skin fibroblasts as a model of Parkinson's disease [PDF]

, 2012
Parkinson's disease is the second most frequent neurodegenerative disorder. While most cases occur sporadic mutations in a growing number of genes including Parkin (PARK2) and PINK1 (PARK6) have been associated with the disease.
A Grunewald, A Grunewald, A Petit, A Rakovic, A Sajadi, A Sprenger, AL Fridman, AL Fridman, AW Michell, B Stefano Di, Blas Morales-Gordo, C Mytilineou, C Piccoli, CA Costa da, CM Clements, DP Narendra, DT Woodley, E Fernandez-Espejo, EM Valente, F Pan-Montojo, F Soldner, FR Wiedemann, G Tesco, Georg Auburger, GP Connolly, H Braak, H Jiang, H Mortiboys, Heinz Reichmann, HH Hoepken, HH Hoepken, HM Huang, HM Huang, IF Khan, IH Park, J Hoenicka, J Waak, Jessica Drost, JM Harper, K Bayreuther, K Gorner, K Isobe, K Winkler-Stuck, Katrin Marcus, KH Narsinh, L Gasparini, L Grandoso, LS Tain, M Garcia-Arencibia, M Ikemura, M Jendrach, M Klinkenberg, M Sun, M Varma, M Wernig, Marina Jendrach, MB Graeber, MC Maj, Michael Klinkenberg, N Exner, N Hirashima, O Rothfuss, P Hoyo del, P Rieske, R Djaldetti, R Musanti, S Geisler, S Gispert, S Kaneko, S Mai, SM Hussein, Suzana Gispert, T Amo, T Gasser, T Shishido, Ulrich Brandt, Vania Broccoli, WG Tatton, Wolfram S. Kunz, WY Lee, Y Miki, Y Ren, Y Ren, YC Kim, Z Jingzhong   +84 more
core   +1 more source

ALDOA Promotes Glycolysis and NLRP3/GSDMD Pyroptosis to Accelerate ALS Progression

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Amyotrophic lateral sclerosis (ALS) is characterized by progressive motor neuron degeneration. Glycolytic dysregulation is implicated in disease progression, yet the underlying mechanisms remain unclear. This study investigates how Aldolase A (ALDOA) drives ALS progression through glycolysis‐mediated motor neuron pyroptosis.
Kaixin Yan, Yan Jiang, Yuxuan Yong, Tianshuo Zhang, Niannian Zhang, Qianqian Zeng, Xue Gong, Li Meng, Fangfang Bi, Yongmin Liu   +9 more
wiley   +1 more source

Pathogenesis and pathophysiology of functional (psychogenic) movement disorders

Neurobiology of Disease, 2019
Functional movement disorders (FMDs), known over time as “hysteria”, “dissociative”, “conversion”, “somatoform”, “non-organic” and “psychogenic” disorders, are characterized by having a voluntary quality, being modifiable by attention and distraction but
José Fidel Baizabal-Carvallo, Mark Hallett, Joseph Jankovic   +2 more
doaj   +1 more source

Statin usage, vascular diagnosis and vascular risk factors in Parkinson's disease [PDF]

, 2017
Background and aims: Vascular disease is a common comorbidity in Parkinson’s disease patients. Statins are potentially neuroprotective for Parkinson’s disease through non-vascular mechanisms.
Cheng, Kelvin K.W., Grosset, Donald G., Grosset, Katherine A., Swallow, Diane M.A.   +3 more
core   +1 more source